Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

Cannabinoid receptors CB1 and CB2 form functional heteromers in brain.

Callén L, Moreno E, Barroso-Chinea P, Moreno-Delgado D, Cortés A, Mallol J, Casadó V, Lanciego JL, Franco R, Lluis C, Canela EI, McCormick PJ.

J Biol Chem. 2012 Jun 15;287(25):20851-65. doi: 10.1074/jbc.M111.335273. Epub 2012 Apr 24.

2.
3.

Activation of cannabinoid CB1 receptors suppresses the ROS-induced hypersensitivity of rat vagal lung C-fiber afferents.

Yeh CM, Ruan T, Lin YJ, Hsu TH.

Pulm Pharmacol Ther. 2016 Oct;40:22-9. doi: 10.1016/j.pupt.2016.06.002. Epub 2016 Jun 18.

PMID:
27328978
4.

Antagonistic cannabinoid CB1/dopamine D2 receptor interactions in striatal CB1/D2 heteromers. A combined neurochemical and behavioral analysis.

Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska M, Bellido I, Tanganelli S, Müller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K.

Neuropharmacology. 2008 Apr;54(5):815-23. doi: 10.1016/j.neuropharm.2007.12.011. Epub 2008 Jan 9.

PMID:
18262573
5.

Cannabinoid-induced enhanced interaction and protein levels of serotonin 5-HT(2A) and dopamine D₂ receptors in rat prefrontal cortex.

Franklin JM, Carrasco GA.

J Psychopharmacol. 2012 Oct;26(10):1333-47. doi: 10.1177/0269881112450786. Epub 2012 Jul 11.

6.

Pharmacological and molecular characterization of a dorsal root ganglion cell line expressing cannabinoid CB(1) and CB(2) receptors.

Fan Y, Hooker BA, Garrison TR, El-Kouhen OF, Idler KB, Holley-Shanks RR, Meyer MD, Yao BB.

Eur J Pharmacol. 2011 Jun 1;659(2-3):161-8. doi: 10.1016/j.ejphar.2011.03.020. Epub 2011 Mar 31.

PMID:
21458448
7.

In vitro and in vivo pharmacology of synthetic olivetol- or resorcinol-derived cannabinoid receptor ligands.

Cascio MG, Bisogno T, Palazzo E, Thomas A, van der Stelt M, Brizzi A, de Novellis V, Marabese I, Ross R, van de Doelen T, Brizzi V, Pertwee R, Maione S, Di Marzo V.

Br J Pharmacol. 2006 Oct;149(4):431-40. Epub 2006 Sep 4.

8.

Cannabinoid receptor agonists modulate oligodendrocyte differentiation by activating PI3K/Akt and the mammalian target of rapamycin (mTOR) pathways.

Gomez O, Sanchez-Rodriguez A, Le M, Sanchez-Caro C, Molina-Holgado F, Molina-Holgado E.

Br J Pharmacol. 2011 Aug;163(7):1520-32. doi: 10.1111/j.1476-5381.2011.01414.x.

9.

Mechanisms for the coupling of cannabinoid receptors to intracellular calcium mobilization in rat insulinoma beta-cells.

De Petrocellis L, Marini P, Matias I, Moriello AS, Starowicz K, Cristino L, Nigam S, Di Marzo V.

Exp Cell Res. 2007 Aug 15;313(14):2993-3004. Epub 2007 May 18.

PMID:
17585904
10.

CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling.

Palazuelos J, Ortega Z, Díaz-Alonso J, Guzmán M, Galve-Roperh I.

J Biol Chem. 2012 Jan 6;287(2):1198-209. doi: 10.1074/jbc.M111.291294. Epub 2011 Nov 18.

11.

Effects of exogenous and endogenous cannabinoids on GABAergic neurotransmission between the caudate-putamen and the globus pallidus in the mouse.

Engler B, Freiman I, Urbanski M, Szabo B.

J Pharmacol Exp Ther. 2006 Feb;316(2):608-17. Epub 2005 Oct 7.

12.

A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents.

Cluny NL, Vemuri VK, Chambers AP, Limebeer CL, Bedard H, Wood JT, Lutz B, Zimmer A, Parker LA, Makriyannis A, Sharkey KA.

Br J Pharmacol. 2010 Oct;161(3):629-42. doi: 10.1111/j.1476-5381.2010.00908.x.

13.

Cannabinoid receptor agonists upregulate and enhance serotonin 2A (5-HT(2A)) receptor activity via ERK1/2 signaling.

Franklin JM, Carrasco GA.

Synapse. 2013 Mar;67(3):145-59. doi: 10.1002/syn.21626. Epub 2012 Dec 8.

14.

Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.

Xu JJ, Diaz P, Astruc-Diaz F, Craig S, Munoz E, Naguib M.

Anesth Analg. 2010 Jul;111(1):99-109. doi: 10.1213/ANE.0b013e3181e0cdaf. Epub 2010 Jun 3.

15.

CB1 and CB2 contribute to antinociceptive and anti-inflammatory effects of electroacupuncture on experimental arthritis of the rat temporomandibular joint.

Gondim DV, Araújo JC, Cavalcante AL, Havt A, Quetz Jda S, Brito GA, Ribeiro Rde A, Lima Vale M.

Can J Physiol Pharmacol. 2012 Nov;90(11):1479-89. doi: 10.1139/y2012-130. Epub 2012 Nov 9.

PMID:
23181276
16.

Cannabinoid agonists increase the interaction between β-Arrestin 2 and ERK1/2 and upregulate β-Arrestin 2 and 5-HT(2A) receptors.

Franklin JM, Vasiljevik T, Prisinzano TE, Carrasco GA.

Pharmacol Res. 2013 Feb;68(1):46-58. doi: 10.1016/j.phrs.2012.11.002. Epub 2012 Nov 19.

17.

Structural determinants in the second intracellular loop of the human cannabinoid CB1 receptor mediate selective coupling to G(s) and G(i).

Chen XP, Yang W, Fan Y, Luo JS, Hong K, Wang Z, Yan JF, Chen X, Lu JX, Benovic JL, Zhou NM.

Br J Pharmacol. 2010 Dec;161(8):1817-34. doi: 10.1111/j.1476-5381.2010.01006.x.

18.

Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines.

Brown I, Cascio MG, Wahle KW, Smoum R, Mechoulam R, Ross RA, Pertwee RG, Heys SD.

Carcinogenesis. 2010 Sep;31(9):1584-91. doi: 10.1093/carcin/bgq151. Epub 2010 Jul 25.

19.

Chromenopyrazoles: non-psychoactive and selective CB₁ cannabinoid agonists with peripheral antinociceptive properties.

Cumella J, Hernández-Folgado L, Girón R, Sánchez E, Morales P, Hurst DP, Gómez-Cañas M, Gómez-Ruiz M, Pinto DC, Goya P, Reggio PH, Martin MI, Fernández-Ruiz J, Silva AM, Jagerovic N.

ChemMedChem. 2012 Mar 5;7(3):452-63. doi: 10.1002/cmdc.201100568. Epub 2012 Feb 2.

20.

Activation of cannabinoid receptor 2 reduces inflammation in acute experimental pancreatitis via intra-acinar activation of p38 and MK2-dependent mechanisms.

Michler T, Storr M, Kramer J, Ochs S, Malo A, Reu S, Göke B, Schäfer C.

Am J Physiol Gastrointest Liver Physiol. 2013 Jan 15;304(2):G181-92. doi: 10.1152/ajpgi.00133.2012. Epub 2012 Nov 8.

Supplemental Content

Support Center